V
Vinay K. Puduvalli
Researcher at University of Texas MD Anderson Cancer Center
Publications - 178
Citations - 5782
Vinay K. Puduvalli is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 37, co-authored 147 publications receiving 4626 citations. Previous affiliations of Vinay K. Puduvalli include Ohio State University & The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick,Vinay K. Puduvalli,Marc C. Chamberlain,Martin J. van den Bent,Antoine F. Carpentier,Lawrence Cher,Warren P. Mason,Michael Weller,Shengyan Hong,Luna Musib,Astra M. Liepa,Donald Thornton,Howard A. Fine +12 more
TL;DR: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.
Journal ArticleDOI
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen,W. K. Alfred Yung,Kathleen R. Lamborn,Patricia L. M. Dahia,Yanfeng Wang,Bin Peng,Lauren E. Abrey,Jeffrey J. Raizer,Timothy F. Cloughesy,Karen Fink,Mark R. Gilbert,Susan M. Chang,Larry Junck,David Schiff,Frank S. Lieberman,Howard A. Fine,Minesh P. Mehta,H. Ian Robins,Lisa M. DeAngelis,Morris D. Groves,Vinay K. Puduvalli,Victor A. Levin,Charles A. Conrad,Elizabeth A. Maher,Kenneth Aldape,Michael Hayes,Laurie Letvak,Merrill J. Egorin,Renaud Capdeville,Richard Kaplan,Anthony J. Murgo,Charles D. Stiles,Michael D. Prados +32 more
TL;DR: YP3A4 inducers, such as EIAEDs, substantially decreased plasma exposure ofImatinib and should be avoided in patients receiving imatinib for chronic myelogenous leukemia and gastrointestinal stromal tumors.
Journal ArticleDOI
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Louis B. Nabors,Jana Portnow,Manmeet Ahluwalia,Joachim Baehring,Henry Brem,Steven Brem,Nicholas Butowski,Jian Campian,Stephen W. Clark,Andrew J. Fabiano,Peter A. Forsyth,Jona A. Hattangadi-Gluth,Matthias Holdhoff,Craig Horbinski,Larry Junck,Thomas Kaley,Priya Kumthekar,Jay S. Loeffler,Maciej M. Mrugala,Seema Nagpal,Manjari Pandey,Ian F. Parney,Katherine B. Peters,Vinay K. Puduvalli,Ian Robins,Jason K. Rockhill,Chad G. Rusthoven,Nicole Shonka,Dennis C. Shrieve,Lode J. Swinnen,Stephanie E. Weiss,Patrick Y. Wen,Nicole Willmarth,Mary Anne Bergman,Susan Darlow +34 more
TL;DR: NCCN Guidelines recommendations for WHO grade I, II, III, and IV gliomas are described and treatment of brain metastases, the most common intracranial tumors in adults, is described.
Journal ArticleDOI
Phase II Trial of Temozolomide Plus the Matrix Metalloproteinase Inhibitor, Marimastat, in Recurrent and Progressive Glioblastoma Multiforme
Morris D. Groves,Vinay K. Puduvalli,Kenneth R. Hess,Kurt A. Jaeckle,Pamela Peterson,W. K. Alfred Yung,Victor A. Levin +6 more
TL;DR: The combination of TMZ and MRM resulted in a PFS at 6 months that exceeded the literature target by 29%.
Journal ArticleDOI
Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience.
Ivo W. Tremont-Lukats,George C. Bobustuc,George K. Lagos,Konstantinos Lolas,Athanassios P. Kyritsis,Vinay K. Puduvalli +5 more
TL;DR: The objective of this study was to estimate the incidence and describe distribution, clinical presentation, and prognosis of brain metastases in patients with prostrate carcinoma who were seen at The University of Texas M. D. Anderson Cancer Center.